An Attention Deficit Hyperactivity Disorder (ADHD) drug boosts norepinephrine levels in the brain. Researchers believe that this will slow the development of senile dementia.
Scientists from the Emory Brine Health Center have concluded that the drug atomoxetine, created to combat attention deficit hyperactivity 
disorder (ADHD), can slow the progression of Alzheimer’s disease. This is the most common type of senile dementia, which develops due to the death of brain neurons and disruption of connections between neural networks. Tau proteins, which accumulate in nodes in the brain, contribute to this disease.
During the study, 39 patients with mild cognitive impairment received atomoxetine therapy for 6 months. The drug reduced inflammation, as well as the amount of tau proteins in the cerebrospinal fluid. Scientists believe that atomoxetine can increase the level of norepinephrine in the brain, and this will slow down the development of an insidious disease. Note that this drug has been used as an approved treatment for ADHD https://en.wikipedia.org/wiki/Attention_deficit_hyperactivity_disorder in the US for more than two decades.
Previous experiments using laboratory rats and mice have shown that high levels of noradrenaline have a positive effect on cognitive function. This is what makes atomoxetine a very promising drug, but more research is needed to use it in this direction.
